- Home
- TTGT vs LXRX Comparison
TTGT vs LXRX Comparison
Compare TTGT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- LXRX
- Stock Information
- Founded
- TTGT 1999
- LXRX 1995
- Country
- TTGT United States
- LXRX United States
- Employees
- TTGT N/A
- LXRX N/A
- Industry
- TTGT Telecommunications Equipment
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- LXRX Health Care
- Exchange
- TTGT Nasdaq
- LXRX Nasdaq
- Market Cap
- TTGT 598.8M
- LXRX 228.8M
- IPO Year
- TTGT 2007
- LXRX 2000
- Fundamental
- Price
- TTGT $7.32
- LXRX $1.08
- Analyst Decision
- TTGT Buy
- LXRX Buy
- Analyst Count
- TTGT 6
- LXRX 4
- Target Price
- TTGT $19.33
- LXRX $3.67
- AVG Volume (30 Days)
- TTGT 549.6K
- LXRX 5.1M
- Earning Date
- TTGT 08-07-2025
- LXRX 07-31-2025
- Dividend Yield
- TTGT N/A
- LXRX N/A
- EPS Growth
- TTGT N/A
- LXRX N/A
- EPS
- TTGT N/A
- LXRX N/A
- Revenue
- TTGT $330,125,000.00
- LXRX $31,213,000.00
- Revenue This Year
- TTGT $76.52
- LXRX N/A
- Revenue Next Year
- TTGT N/A
- LXRX N/A
- P/E Ratio
- TTGT N/A
- LXRX N/A
- Revenue Growth
- TTGT 29.33
- LXRX 1251.21
- 52 Week Low
- TTGT $6.49
- LXRX $0.28
- 52 Week High
- TTGT $33.08
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- TTGT 50.56
- LXRX 66.94
- Support Level
- TTGT $6.49
- LXRX $0.84
- Resistance Level
- TTGT $7.37
- LXRX $1.19
- Average True Range (ATR)
- TTGT 0.46
- LXRX 0.09
- MACD
- TTGT 0.05
- LXRX 0.02
- Stochastic Oscillator
- TTGT 45.86
- LXRX 76.60
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.